Windlas Biotech (NSE:WINDLAS) Stock Based Compensation: ₹0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:WINDLAS Windlas Biotech Ltd NSE:WINDLAS
90 GF Score
Price ₹851.05
GF Value ₹940.70
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Windlas Biotech Stock Based Compensation?

Windlas Biotech NSE:WINDLAS -0.14% 90 Stock Based Compensation is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:WINDLAS with a GF Score™ of 90/100 and a GF Value™ of ₹940.70 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Windlas Biotech's Stock Based Compensation for the three months ended in Mar. 2026 was ₹0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Windlas Biotech Stock Based Compensation Related Terms

Windlas Biotech Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Windlas Biotech's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windlas Biotech Stock Based Compensation Chart

Windlas Biotech Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Stock Based Compensation
Get a 7-Day Free Trial 18.13 10.08 20.67 24.60 166.11

Windlas Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:WINDLAS
90GF Score
Windlas Biotech Ltd NSE:WINDLAS
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Windlas Biotech Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

What does a Stock Based Compensation of ₹0 Mil mean?
Windlas Biotech (NSE:WINDLAS) has a Stock Based Compensation of ₹0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Windlas Biotech and its competitors.
Is Windlas Biotech's Stock Based Compensation too high?
Windlas Biotech's current Stock Based Compensation is ₹0 Mil. Overall, Windlas Biotech has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Stock Based Compensation compare to ZTS and UTHR?
Windlas Biotech's Stock Based Compensation of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Windlas Biotech and its competitors. Windlas Biotech's current Stock Based Compensation is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹940.70, compared to a current price of ₹851.05 — trading 9.5% below its estimated fair value. The current Stock Based Compensation is ₹0 Mil. Windlas Biotech's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Stock Based Compensation is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?

Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued. The current stock price of ₹851.05 is trading 9.5% below its estimated GF Value™ of ₹940.70. GuruFocus considers Windlas Biotech to be Modestly Undervalued.

Key valuation signals for NSE:WINDLAS:

  • Stock Based Compensation: ₹0 Mil
  • GF Value™: ₹940.70 vs. price of ₹851.05 (9.5% below fair value)
  • GF Score™: 90/100 with 1 warning sign

No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Windlas Biotech Business Description

Other Exchanges 543329:India
Address Golf Course Extension Road, 705-706, Vatika Professional Point, Sector-66, Gurgaon, HR, IND, 122 001
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
90GF Score

Get the complete analysis for NSE:WINDLAS

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹851.05
Price
₹940.70
GF Value